Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

NCT01990209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Orteronel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]